Physician profile
Elyse Dewitt
NPI 1417479718
$6,271.49
in general payments reported to CMS, 2019-2025
17 companies · $752 in 2025
The $752 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $307 · 2021: $950 · 2022: $1,080 · 2023: $1,057 · 2024: $1,010 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601 · Entertainment: $120 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,600.94 |
| Entertainment | $120.45 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,879.27 | 2019-2025 | Total30, Precision 1, Precision7 |
| Coopervision INC. | $1,343.06 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,032.32 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $369.98 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $240.84 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $209.37 | 2021-2023 | Cequa |
| Mallinckrodt Hospital Products INC. | $196.24 | 2023 | Acthar |
| Astellas Pharma US INC | $166.50 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $154.87 | 2022-2024 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $127.04 | 2021-2022 | |
| Optos, INC. | $120.45 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Amgen INC. | $117.74 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $114.77 | 2022 | |
| Novartis Pharmaceuticals Corporation | $58.14 | 2021-2022 | |
| Dompe US, INC. | $58.01 | 2025 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $47.02 | 2020-2022 | |
| Abbvie INC. | $35.87 | 2023-2025 | Lumigan, Alphagan P |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elyse Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.